{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:37:16Z","timestamp":1793979436242,"version":"4.8.0"},"reference-count":35,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ci\u00eanc. sa\u00fade coletiva"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:p>A erradica\u00e7\u00e3o da var\u00edola foi a maior conquista da sa\u00fade p\u00fablica mundial. E o bin\u00f4mio vacinas e imuniza\u00e7\u00f5es continua a demonstrar alto desempenho na preven\u00e7\u00e3o e no controle de outras doen\u00e7as imunopreven\u00edveis. As novas iniciativas globais em vacina\u00e7\u00e3o, como a GAVI, v\u00eam possibilitando a introdu\u00e7\u00e3o de novas vacinas e salvando vidas de milhares de crian\u00e7as nos pa\u00edses mais pobres do mundo. O Programa Nacional de Imuniza\u00e7\u00f5es (PNI) do Brasil tamb\u00e9m vem sendo fortalecido com a incorpora\u00e7\u00e3o de novas vacinas no seu calend\u00e1rio de imuniza\u00e7\u00f5es, como a vacina contra rotav\u00edrus, pneumococos conjugada, meningite meningoc\u00f3cica do sorogrupo C conjugada, al\u00e9m do H1N1 para as popula\u00e7\u00f5es de maior risco. Com o descobrimento de novas vacinas de alto valor agregado, os grandes laborat\u00f3rios multinacionais despertaram para este segmento farmac\u00eautico e buscam a lideran\u00e7a da \u00e1rea, investindo maci\u00e7amente em inova\u00e7\u00e3o tecnol\u00f3gica, al\u00e9m de realizar fus\u00f5es, aquisi\u00e7\u00f5es e parcerias tecnol\u00f3gicas. O Brasil tamb\u00e9m vem se fortalecendo, tendo criado marcos reguladores e financiando projetos de inova\u00e7\u00e3o tecnol\u00f3gica e moderniza\u00e7\u00e3o da infraestrutura de produ\u00e7\u00e3o.<\/jats:p>","DOI":"10.1590\/s1413-81232011000200008","type":"journal-article","created":{"date-parts":[[2011,4,9]],"date-time":"2011-04-09T19:35:29Z","timestamp":1302377729000},"page":"445-458","source":"Crossref","is-referenced-by-count":24,"title":["Atualiza\u00e7\u00e3o em vacinas, imuniza\u00e7\u00f5es e inova\u00e7\u00e3o tecnol\u00f3gica"],"prefix":"10.1590","volume":"16","author":[{"given":"Akira","family":"Homma","sequence":"first","affiliation":[{"name":"Instituto de Tecnologia em Imunobiol\u00f3gicos de Bio-Manguinhos"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinaldo de Menezes","family":"Martins","sequence":"additional","affiliation":[{"name":"Instituto de Tecnologia em Imunobiol\u00f3gicos de Bio-Manguinhos"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria da Luz Fernandes","family":"Leal","sequence":"additional","affiliation":[{"name":"Instituto de Tecnologia em Imunobiol\u00f3gicos de Bio-Manguinhos"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos da Silva","family":"Freire","sequence":"additional","affiliation":[{"name":"Instituto de Tecnologia em Imunobiol\u00f3gicos de Bio-Manguinhos"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur Roberto","family":"Couto","sequence":"additional","affiliation":[{"name":"Instituto de Tecnologia em Imunobiol\u00f3gicos de Bio-Manguinhos"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","series-title":"Vaccines","first-page":"1","volume-title":"A short history of vaccination","author":"Plotkin SL","year":"2008","edition":"5"},{"issue":"Supl.2","key":"ref2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1590\/S0104-59702003000500011","article-title":"Desenvolvimento tecnol\u00f3gico: elo deficiente na inova\u00e7\u00e3o tecnol\u00f3gica de vacinas","volume":"10","author":"Homma A","year":"2003","journal-title":"Historia Ci\u00eancias Sa\u00fade Manguinhos"},{"key":"ref3","series-title":"Vaccinated: one man's quest to defeat the world's deadliest diseases","author":"Offit PA","year":"2008"},{"key":"ref4","series-title":"State of the world's vaccines and immunization","year":"2009","edition":"3"},{"key":"ref5","year":"2010"},{"key":"ref6","year":"2010"},{"key":"ref7","year":"2010"},{"key":"ref8","year":"2010"},{"key":"ref9","year":"2010"},{"key":"ref10","year":"2010"},{"key":"ref11","year":"2010"},{"key":"ref12","year":"2010"},{"key":"ref13","year":"2010"},{"key":"ref14","series-title":"Programa de vacina\u00e7\u00e3o","year":"2010"},{"key":"ref15","series-title":"Immunization newsletter: The ProVac Initiative","year":"2009"},{"key":"ref16","series-title":"Valor Econ\u00f4mico 2010","author":"Scaramuzzo M.","year":"2010"},{"key":"ref17","year":"2010"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.vaccine.2009.12.036","article-title":"The role of emerging manufacturers in access to innovative vaccines of public health importance","volume":"28","author":"Milstien JB","year":"2010","journal-title":"Vaccine","ISSN":"https:\/\/id.crossref.org\/issn\/0264-410X","issn-type":"print"},{"key":"ref19","series-title":"The Jordan Report","year":"2002"},{"key":"ref20","year":"2010"},{"key":"ref21","series-title":"PATH: a catalyst for global health","year":"2010"},{"key":"ref22","series-title":"International Aids Vaccine Initiative","year":"2010"},{"key":"ref23","year":"2010"},{"key":"ref24","series-title":"Vaccines","first-page":"1357","volume-title":"Alternative vaccine delivery methods","author":"Weniger BG","year":"2008","edition":"5"},{"key":"ref25","series-title":"Inova\u00e7\u00e3o em Sa\u00fade","author":"Azevedo N","year":"2007"},{"key":"ref26","series-title":"Vacinas, soros & imuniza\u00e7\u00f5es","first-page":"269","volume-title":"Programa Nacional de Competitividade em Vacinas (Inovacina)","author":"Carvalheiro JR","year":"2005"},{"key":"ref27","series-title":"Resolu\u00e7\u00e3o RDC n\u00ba 4, de 10 de fevereiro de 2009","year":"2009"},{"key":"ref28","article-title":"Consulta P\u00fablica n\u00ba 3, de 13 de janeiro de 200. Resolu\u00e7\u00e3o-RDC que disp\u00f5e sobre boas pr\u00e1ticas de fabrica\u00e7\u00e3o de medicamentos (revoga\u00e7\u00e3o da RDC 210\/03)","year":"2009","journal-title":"Di\u00e1rio Oficial da Uni\u00e3o"},{"key":"ref29","year":"2010"},{"key":"ref30","series-title":"Declara\u00e7\u00e3o de Helsinque","year":"1964"},{"key":"ref31","series-title":"International ethical guidelines for biomedical research involving human subjects","year":"2002"},{"key":"ref32","series-title":"The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)","year":"2010"},{"key":"ref33","year":"2010"},{"issue":"16","key":"ref34","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.vaccine.2008.11.036","article-title":"Brighton Collaboration Methods Working Group: Guidelines for collection, analysis and presentation of vaccine safety data in pre and post licensure clinical studies","volume":"27","author":"Bonhoeffer J","year":"2009","journal-title":"Vaccine","ISSN":"https:\/\/id.crossref.org\/issn\/0264-410X","issn-type":"print"},{"key":"ref35","series-title":"Boas Pr\u00e1ticas Cl\u00ednicas: Documento das Am\u00e9ricas","year":"2005"}],"container-title":["Ci\u00eancia &amp; Sa\u00fade Coletiva"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/csc\/v16n2\/v16n2a08.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T15:51:32Z","timestamp":1495813892000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1413-81232011000200008&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S1413-81232011000200008"],"URL":"https:\/\/doi.org\/10.1590\/s1413-81232011000200008","relation":{},"ISSN":["1413-8123"],"issn-type":[{"value":"1413-8123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}